Slow release isn’t just about numbers on a dashboard. It directly affects:

• Working capital: Batches sit in quarantine, tying up millions.
• Client trust: Strategic partners doubt your ability to deliver.
• Margins: Late deliveries trigger financial penalties.
• Focus: QA and QPs spend more time firefighting than preventing problems.

The longer timelines persist, the more credibility your Quality team loses.

 Mistake 1: Treating It as a Resource Problem

The instinct is to hire more QA reviewers. But if deviations are poorly investigated, adding reviewers just means reviewing more bad documentation.

 Mistake 2: Overengineering the MBR

Complex batch records are meant to prevent errors. In reality, they often create them. Overloaded MBRs slow down review cycles and confuse operators.

 Mistake 3: Ignoring the Role of QPs

Too often, Qualified Persons act as late-stage signers instead of upstream quality partners. By the time they see a batch, risks have already accumulated.

 Mistake 4: Chasing Metrics Instead of Root Causes

Leaders push teams to “go faster” or close CAPAs quickly. But if root cause analysis is weak, deviations repeat — and timelines stretch even further.

Each of these missteps explains why so many attempts at batch release time reduction in biopharma fail.